Translations:GLP1 poly-agonist peptides/1/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
FuzzyBot (talk | contribs)
Importing a new version from external source
 
(No difference)

Latest revision as of 22:01, 2 April 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP1 poly-agonist peptides)
'''GLP1 poly-agonist peptides''' are a class of drugs that activate multiple [[peptide hormone]] receptors including the [[glucagon-like peptide-1 receptor|glucagon-like peptide-1 (GLP-1) receptor]]. These drugs are developed for the same indications as [[GLP-1 receptor agonist]]s—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of [[bariatric surgery]]. The first such drug to receive approval is [[tirzepatide]], a dual agonist of GLP-1 and [[GIP receptor]]s.

GLP1 poly-agonist peptides are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which are dose-limited by gastrointestinal disturbances. The effectiveness of multi-receptor agonists could possibly equal or exceed that of bariatric surgery. The first such drug to receive approval is tirzepatide, a dual agonist of GLP-1 and GIP receptors.